secwatch.observer — SEC 8-K summary
======================================

Issuer:     Prime Medicine, Inc. (PRME)
CIK:        0001894562
Form:       8-K
Filed at:   2025-05-19T23:59:59+00:00
Accession:  0001193125-25-122156
Event type: other_material
Sentiment:  positive
Materiality: 1.00
Item codes: 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prime Medicine CEO Gottesdiener resigns; Reine named CEO; positive CGD data; restructures to liver focus
--------------------------------------------------------------------------------

- Keith Gottesdiener resigned as CEO and board member; CFO Allan Reine appointed CEO and to board, effective May 19, 2025.
- Jeff Marrazzo named Executive Chair of the board.
- First clinical data for PM359 in CGD: 58% DHR positivity at Day15, 66% at Day30, well above 20% threshold; rapid engraftment.
- Company to deprioritize CGD programs, seek partner for PM359; focus on Wilson's Disease and AATD with IND/CTA in 1H2026 and mid-2026.
- Workforce reduction and cost cutting to reduce cash needs; Beam arbitration ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/0001193125-25-122156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1894562/000119312525122156/d863812d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-122156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer